Patents by Inventor Martin G. Pomper

Martin G. Pomper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200216402
    Abstract: Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
    Type: Application
    Filed: March 16, 2020
    Publication date: July 9, 2020
    Inventors: Martin G. Pomper, Ronnie C. Mease, Ying Chen, Sangeeta Ray
  • Patent number: 10695319
    Abstract: Provided are compounds generated by conjugation of triptolide with glucose to form glucose-triptolide conjugates, provides compounds with effective anti-proliferative activity and improved tolerability as compared to naturally occurring triptolide compounds.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: June 30, 2020
    Assignees: The Johns Hopkins University, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences
    Inventors: Jun Liu, Qingli He, Martin G. Pomper, Il Minn, Biao Yu, Qiaoling Wang
  • Patent number: 10688198
    Abstract: Salicylic acid-based polymeric CEST contrast agents targeting prostate-specific membrane antigen, pharmaceutical composition comprising the same and methods of use thereof are disclosed.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: June 23, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Sangeeta Ray, Xing Yang, Xiaolei Song, Michael T. McMahon, Martin G. Pomper
  • Patent number: 10683272
    Abstract: Low-molecular weight gadolinium (Gd)-based MR contrast agents for PSMA-specific Ti-weighted MR imaging are disclosed. The (Gd)-based MR contrast agents exhibit high binding affinity for PSMA and exhibit specific Ti contrast enhancement at PSMA+ cells. The PSMA-targeted Gd-based MR contrast agents can be used for PSMA-targeted imaging in vivo. 86Y-labeled PSMA-binding ureas also are provided, wherein the PSMA-binding ureas also are suitable for use with other radiotherapeutics.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: June 16, 2020
    Assignees: THE JOHNS HOPKINS UNIVERSITY, NORTHWESTERN UNIVERSITY
    Inventors: Sangeeta Ray, Martin G. Pomper, Thomas J. Meade, Ronnie C. Mease, Ying Chen, Xing Yang, Matthew Rotz
  • Publication number: 20200170960
    Abstract: The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor.
    Type: Application
    Filed: July 8, 2019
    Publication date: June 4, 2020
    Inventors: Sachin S. Chandran, Sangeeta Ray, Martin G. Pomper, Samuel R. Denmeade, Ronnie C. Mease
  • Publication number: 20200155713
    Abstract: Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer are disclosed.
    Type: Application
    Filed: March 22, 2017
    Publication date: May 21, 2020
    Inventors: SANGEETA RAY, MARTIN G. POMPER
  • Patent number: 10653806
    Abstract: The present invention provides bivalent and multivalent ligands with a view to improving the affinity and pharmacokinetic properties of a urea class of PSMA inhibitors. The compounds and their synthesis can be generalized to multivalent compounds of other target antigens. Because they present multiple copies of the pharmacophore, multivalent ligands can bind to receptors with high avidity and affinity, thereby serving as powerful inhibitors. The modular multivalent scaffolds of the present invention, in one or more embodiments, contains a lysine-based (?-, ?-) dialkyne residue for incorporating two or more antigen binding moieties, such as PSMA binding Lys-Glu urea moieties, exploiting click chemistry and one or more additional lysine residues for subsequent modification with an imaging and/or therapeutic nuclides or a cytotoxic ligands for tumor cell killing.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: May 19, 2020
    Assignee: The Johns Hopkins University
    Inventors: Martin G. Pomper, Sangeeta Ray, Ronnie C. Mease, Hassan Shallal
  • Publication number: 20200140831
    Abstract: A DNA plasmid useful for diagnostic and therapeutic gene therapy is disclosed. Improvements to gene therapy methods known in the art are provided to ensure cancer-targeting, high efficacy, and long durability of expression. The DNA plasmid is combined with compositions of polymeric nanoparticles for non-viral gene therapy to treat cancer, including hepatocellular carcinoma and prostate cancer.
    Type: Application
    Filed: October 1, 2019
    Publication date: May 7, 2020
    Inventors: Jordan J. Green, Martin G. Pomper, Camila Gadens Zamboni, Hannah Vaughan, Il Minn
  • Publication number: 20200109124
    Abstract: Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
    Type: Application
    Filed: December 5, 2019
    Publication date: April 9, 2020
    Inventors: Martin G. Pomper, Ronnie C. Mease, Ying Chen, Sangeeta Ray, Jonathan Sorger
  • Patent number: 10500292
    Abstract: Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: December 10, 2019
    Assignee: The Johns Hopkins University
    Inventors: Martin G. Pomper, Ronnie Charles Mease, Ying Chen
  • Publication number: 20190330367
    Abstract: The presently disclosed subject matter provides compositions and methods comprising isolated antibodies that can recognize human prostate-specific membrane antigen (PSMA). The presently disclosed antibodies can be used to for imaging and therapy of PSMA-expressing cancers, such as prostate cancer, in a subject.
    Type: Application
    Filed: January 5, 2018
    Publication date: October 31, 2019
    Inventors: Cyril Barinka, Martin G. Pomper, Zora Novakova, Catherine A. Foss
  • Patent number: 10426850
    Abstract: The present invention provides both a caged collagen mimetic peptide (CCMP) having the formula: L-S-Zm-[Gly-X-Y]n-LGly-X-Y-[Gly-X-Y]n (SEQ ID NO: 19); wherein L is one or more detectable moieties; S is one or more spacer molecules; Zm is any amino acid where m is an integer of 1 to 10; X is proline or modified proline; Y is proline or modified proline; Gly is glycine; n is an integer from 1 to 20; and LGly is a glycine covalently linked to a cage moiety comprising a labile protecting group, as well as a collagen mimetic peptides lacking the labile protecting group (CMP). The inventions are useful for binding collagen and denatured collagen and/or gelatin both in vitro and in vivo, and are useful for targeting any organ or tissue where collagen is present, and can be used for research and diagnostic imaging (both in vivo and in vitro) and also for in vivo therapeutic applications.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: October 1, 2019
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Michael S. Yu, Yang Li, Daniel Summerfield, Allen Yi-Lan Wang, Catherine A. Foss, Martin G. Pomper
  • Patent number: 10413620
    Abstract: The presently disclosed subject matter provides compositions and kits comprising light-emitting versions of the monoclonal antibody to C3d (mAB 3d29) for imaging and methods of use thereof for detecting infectious and inflammatory cells in vivo. The presently disclosed subject matter also provides methods for detecting and/or monitoring a Mycobacterium tuberculosis (M. tuberculosis) infection in a subject, as well as methods of treating a M. tuberculosis infection in a subject.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: September 17, 2019
    Assignees: The Regents of the University of Colorado, a body corporate, The Johns Hopkins University
    Inventors: Martin G. Pomper, Catherine A. Foss, Joshua M. Thurman, V. Michael Holers
  • Publication number: 20190240355
    Abstract: The presently disclosed subject matter provides compositions and kits comprising light-emitting versions of the monoclonal antibody to C3d (mAB 3d29) for imaging and methods of use thereof for detecting infectious and inflammatory cells in vivo. The presently disclosed subject matter also provides methods for detecting and/or monitoring a Mycobacterium tuberculosis (M. tuberculosis) infection in a subject, as well as methods of treating a M. tuberculosis infection in a subject.
    Type: Application
    Filed: September 15, 2015
    Publication date: August 8, 2019
    Inventors: Martin G. Pomper, Catherine A. Foss, Joshua M. Thurman, V. Michael Holers
  • Patent number: 10369113
    Abstract: The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: August 6, 2019
    Assignee: The Johns Hopkins University
    Inventors: Sachin S. Chandran, Sangeeta Ray, Martin G. Pomper, Samuel R. Denmeade, Ronnie C. Mease
  • Publication number: 20190225589
    Abstract: Triazole conjugated urea-based and thiourea-based scaffolds that have high binding affinity to PSMA are disclosed. These scaffolds can be radiolabeled and used to image cells and tumors that express PSMA. Methods of synthesizing radiofluorinated triazole conjugated urea-based and thiourea-based scaffolds also are disclosed.
    Type: Application
    Filed: August 15, 2016
    Publication date: July 25, 2019
    Inventors: MARTIN G. POMPER, YING CHEN, XING YANG, RONNIE C. MEASE, SANGEETA RAY
  • Publication number: 20190192699
    Abstract: Highly potent and selective radionuclide-based imaging and therapy agents targeting carbonic anhydrase IX with minimum non-specific organ uptake are disclosed. Methods of imaging and/or treating carbonic anhydrase IX-expressing cells or tumors also are disclosed.
    Type: Application
    Filed: May 12, 2017
    Publication date: June 27, 2019
    Inventors: Xing YANG, Il MINN, Steven ROWE, Sangeeta RAY, Ronnie C. MEASE, Michael GORIN, Mohamad ALLAF, Martin G. POMPER
  • Publication number: 20190177275
    Abstract: Methods, and related compositions, for the improved synthesis of [18F]DCFPyL are disclosed. Also provided are methods, and related compositions, for the use of [18F]DCFPyL so produced.
    Type: Application
    Filed: June 9, 2017
    Publication date: June 13, 2019
    Inventors: Hayden T. Ravert, Daniel P. Holt, Ying Chen, Ronnie C. Mease, Hong Fan, Martin G. Pomper, Robert F. Dannals
  • Publication number: 20190134235
    Abstract: Radiofluorinated FNDP for PET imaging of soluble epoxide hydrolase (sEH) and method of using the same are disclosed.
    Type: Application
    Filed: May 4, 2017
    Publication date: May 9, 2019
    Inventors: ANDREW HORTI, MARTIN G. POMPER, NABIL J. ALAYED
  • Publication number: 20190119394
    Abstract: Death receptor 5 (DR5) agonist compositions and methods for treating pancreatitis have been developed. The compositions include Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL), its analogues, and anti-DR5 agonistic antibodies. In certain embodiments, TRAIL analogs and anti-death receptor 5 agonistic antibodies have analgesic and disease modifying effects on the pancreas.
    Type: Application
    Filed: April 7, 2017
    Publication date: April 25, 2019
    Applicant: The Johns Hopkins University
    Inventors: Seulki Lee, Martin G. Pomper, Ogyi Park, Magdalena Scully, Pankaj J. Pasricha